The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted ...

OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

RNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in ...

Shares in the company are trading nearly 54% down compared to pandemic-high prices. Image credit: Shutterstock/ ShU studio.

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

It is common for sponsors to switch digital platforms between clinical trial phases, but sponsors can achieve much by using ...

Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic ...